Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Abstract

Oncogenic transformation of cells by different EGFR mutants causes differential sensitivity to gefitinib and erlotinib. Treatment of lung cancers harboring EGFR exon 20 insertions may therefore require the development of alternative kinase inhibition strategies.